Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Belgium Genetic Centers Partner on WGS-Based Diagnostics; Evercore Upgrades Illumina Shares

NEW YORK – Illumina and the Belgian Genetic Centers said on Tuesday they are partnering to evaluate whole-genome sequencing to diagnose patients with intellectual disabilities and developmental disorders in routine care.

Under the terms of their agreement, the Belgian Resolve Rare Diseases group will run a study recruiting 800 pediatric patients and their parents. Half of the patients and parents will be randomly assigned to the WGS arm and half will receive either whole-exome sequencing or microarray-based diagnosis. The study will also assess the economic impact of WGS.

Illumina will provide sequencing reagents. Financial and other terms of the agreement were not disclosed.

Separately, Illumina announced that it is launching noninvasive prenatal diagnostic testing on the VeriSeq v2 platform in Thailand as part of a partnership with Next Generation Genomic, a genetic testing company in that country.

The news comes as investment bank Evercore ISI upgraded shares of Illumina to an In Line rating with a price target of $400.

In early morning trading on the Nasdaq, shares of Illumina were flat at $406.30.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.